A phase I/II clinical study of expanded autologous NK cell combined with rituximab-based chemotherapy in patients with CD20 positive B-cell lymphoma

A phase I/II clinical study of expanded autologous NK cell combined with rituximab-based chemotherapy in patients with CD20 positive B-cell lymphoma - A phase I/II clinical study of expanded autologous NK cell combined with rituximab-based chemotherapy in patients with B-cell lymphoma

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014072

Enrollment

Registered

2014-06-01

Start date

2014-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

relapsed/refractory CD20 positive B-cell lymphoma

Interventions

Expanded autologous NK cell is administered intravenously on the day after completion of rituximab-based chemotherapy.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Histologically confirmed CD20 positive B-cell lymphoma 2. Patients who are refractory to standard chemotherapy 3. Eastern Cooperative Oncology Group (ECOG) Performance Status is 0-2 4. Expected survival period is more than 3 months 5. Obtaining written informed consent

Exclusion criteria

Exclusion criteria: 1. Patients with active infections 2. Patients with severe complications 3. Pregnant or lactating women 4. Patients with history of severe allergy 5. Patients medicated with the immunosuppressive agents 6. Inappropriate patients for this study judged by the physicians

Design outcomes

Primary

Measure	Time frame
Safety: Evaluation by NCI-CTCAE ver 4.0	—

Secondary

Measure	Time frame
Efficacy: Clinical response rate	—

Countries

Japan

Contacts

Public ContactNorina Tanaka

Tokyo Women's Medical University Department of Hematology

tanaka.norina@twmu.ac.jp03-3353-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026